Alertix Company

Alertix Veterinary Diagnostics AB was founded in 2017. The goal of the company is to commercialize discoveries from Swedish veterinary medical biotech research. In particular concerning a new, powerful method for measuring the presence of the enzyme thymidine kinase 1 (TK1) in serum of animals important in veterinary medicine. TK1 is a biomarker for tumor growth and cell turnover. The substance has been detected in serum of patients even before they show clinical symptoms. This means that the assay can be a valuable tool for early diagnosis of cancer diseases. Unlike previously established methods for detecting TK1 the Alertix method is an immunochemical routine method, which can also successfully detect serum TK1 in patients with solid tumors.
Technology: Others
Industry: Biotechnology, Community and Lifestyle, Health Care, Science and Engineering
Headquarters: Kalmar, Kalmar Lan, Sweden
Founded Date: 2017-01-01
Employees Number: 1-10
Funding Status: Seed
Investors Number: 1
Total Funding: SEK6M
Estimated Revenue: Less than $1M
Last Funding Type: Venture - Series Unknown

Visit Website
info@alertixvet.com
Register and Claim Ownership